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Abstract
Background—Cervical cancer incidence in the United States may be greatly reduced through
widespread human papillomavirus (HPV) vaccination. We estimated the statewide level of HPV
vaccine initiation among adolescent girls in North Carolina and identified correlates of vaccine
initiation.
Methods—We used data from 617 parents of adolescent females from North Carolina who
completed the population-based 2008 Child Health Assessment and Monitoring Program survey.
Analyses used weighted multivariate logistic regression.
Results—Overall, 31.3% of parents reported their daughters had received at least 1 dose of HPV
vaccine. Vaccine initiation was higher among daughters aged 13 to 15 years (odds ratio [OR] =
2.03, 95% CI, 1.12–3.67) or 16 to 17 years (OR = 3.21, 95% CI, 1.76 –5.86) compared with those
10 to 12 years old. Additional correlates of HPV vaccine initiation included the daughter having a
preventive check-up in the last 12 months (OR = 5.09, 95% CI, 2.43–10.67), having received
meningococcal vaccine (OR = 2.50, 95% CI, 1.55– 4.01), or being from an urban area (OR = 1.81,
95% CI, 1.02–3.21). Among parents of unvaccinated daughters, intent to vaccinate in the next year
was higher among those with daughters aged 13 to 17 years. Parents of unvaccinated non-Hispanic
white daughters reported lower levels of intent to vaccinate within the next year compared with
parents of unvaccinated daughters of other races.
Conclusions—HPV vaccine initiation in North Carolina is comparable with other US areas.
Potential strategies for increasing HPV vaccination levels include reducing missed opportunities
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for HPV vaccination at preventive check-ups and increasing concomitant administration of HPV
vaccine with other adolescent vaccines.
Human papillomavirus (HPV) is an extremely common sexually transmitted infection
among women in the United States,1,2 with infection often occurring soon after sexual
debut.3 While most HPV infections spontaneously clear within 1 year,4–6 women with
persistent infections face a higher risk of developing cervical disease. Oncogenic HPV types
are responsible for virtually all cases of cervical cancer, with types 16 and 18 accounting for
approximately 70% of these cancers.7,8 In 2009, there will be an estimated 11,270 incident
cases of cervical cancer in the United States.9 Nononcogenic HPV types 6 and 11 are
associated with more than 90% of cases of anogenital warts,10 which affect approximately
7% of sexually active females.11
The US Food and Drug Administration licensed a quadrivalent HPV vaccine for use in June
2006 to protect against types 6, 11, 16, and 18. The US Advisory Committee on
Immunization Practices currently recommends the 3-dose vaccine regimen be administered
routinely to all females aged 11 to 12 years, but the vaccine may be administered as early as
age 9, with catch-up vaccination for females ages 13 to 26.12 If widespread vaccination is
achieved, cervical cancer incidence may be greatly reduced, perhaps by as much as 77%.8
Recent data from the 2008 National Immunization Survey-Teen found that 37% of female
adolescents aged 13 to 17 years in the United States had received 1 or more doses of HPV
vaccine.13 Although a few studies have identified correlates of HPV vaccine acceptability
among statewide samples,14,15 no study, to our knowledge, has used statewide data to
estimate HPV vaccine initiation and identify correlates of initiation among adolescent girls.
We aimed to generate a population-based estimate of HPV vaccine initiation among
adolescent females from North Carolina. We also sought to examine potential correlates of
vaccine initiation, including characteristics of adolescent females, their caregivers,
households, and counties of residence.
MATERIALS AND METHODS
Study Design
This study used data on North Carolina residents from the 2008 Behavioral Risk Factor
Surveillance System (BRFSS) and 2008 Child Health Assessment and Monitoring Program
(CHAMP) surveys. BRFSS is an annual, population-based telephone survey of health-
related behaviors among noninstitutionalized adults 18 years and older in the United
States.16 The North Carolina State Center for Health Statistics (SCHS) Survey Center uses
random-digit-dialing and a computer-assisted-telephone-interviewing system to conduct
BRFSS surveys. Additional information on BRFSS design and methodology is available
through the Centers for Disease Control and Prevention.16
The SCHS also conducts the CHAMP survey annually to measure the health characteristics
of children in North Carolina less than 18 years old. Interviewers asked adults completing
the BRFSS interview if any children less than 18 years of age lived in their household. For
those with a child in their household, interviewers asked about the child’s date of birth,
Reiter et al. Page 2






















gender, and whether the respondent would complete the CHAMP survey about the child’s
health. If a respondent agreed to participate, an interviewer placed a follow-up call about 2
weeks later to complete the survey with the person identified as being the most
knowledgeable about the child’s health (usually the BRFSS respondent). A preprogrammed
process in the computer- assisted-telephone-interviewing system randomly selected one
child to be the index child for the CHAMP survey in households with more than one child
under the age of 18. We paid to have the CHAMP survey include a section on HPV
vaccination, administered to caregivers whose index child was a female 10 to 17 years of
age. To use caregiver data from the BRFSS survey, we linked data from CHAMP and
BRFSS surveys using a unique identifier.
The response rate for the 2008 BRFSS survey in North Carolina was 60.6%.17 In total, 3865
of 4565 (84.7%) eligible BRFSS households agreed to participate in the CHAMP survey, of
which 2987 (77.3%) completed the survey. All caregivers (n = 700) with age-eligible
daughters who completed the CHAMP survey received HPV vaccine items. Of these, 68
caregivers were not asked about vaccine initiation because they had not heard of HPV
vaccine before the survey (or were unsure if they had heard of it), and 15 either refused to
provide HPV vaccine initiation information or indicated they did not know if their female
child had received HPV vaccine. We report data on HPV vaccine initiation for the remaining
617 female adolescents, as reported by their caregivers. Since most caregivers (94%;
581/617) reported being a parent of the female child, we refer to them as “parents” and the
female children as “daughters.” Of parents completing the CHAMP survey, 81% (502/617)
were the original BRFSS respondents. The Institutional Review Board at the University of
North Carolina determined that this study did not require Institutional Review Board
approval.
Measures
The CHAMP survey assessed HPV vaccine initiation, the main study outcome, using the
item “Has (daughter’s name) had any shots of the HPV vaccine?” Because the survey did
not collect data on the number of vaccine doses received, we focus on vaccine initiation of
having received at least 1 dose, although we acknowledge that 3 doses are required for full
vaccine effectiveness. The CHAMP survey also collected information on where the daughter
received HPV vaccine.
Interviewers asked parents of unvaccinated females the main reason why they had not
initiated HPV vaccine for their daughters. Many parents indicated multiple reasons, all of
which interviewers recorded. The survey collected data on whether parents of unvaccinated
females intended to get their daughter HPV vaccine in the next year with the item “How
likely are you to get the HPV vaccine for (daughter’s name) in the next 12 months?”
Response options (coded 1–4) were “definitely won’t,” “probably won’t,” “probably will,”
and “definitely will.” We recoded responses of “don’t know/not sure” to the midpoint of the
scale.
Interviewers assessed daughter’s age, race/ethnicity (non-Hispanic white, non-Hispanic
black, or other [including Hispanic]), school type, and healthcare coverage during the
CHAMP survey. Parents indicated whether their daughters have a regular healthcare
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provider, had a preventive check-up in the last 12 months, and received meningococcal
vaccine. Interviewers also collected data during the CHAMP survey regarding how often
parents thought children should be seen by a healthcare provider for a regular check-up and
highest education level completed by anyone in the household.
During the BRFSS survey, parents provided information regarding demographics and
whether they had received influenza vaccine (either shot or spray) for themselves in the last
year. Female respondents indicated when their last Pap smear test was and whether they had
received HPV vaccine for themselves (asked only to females aged 18–49 years).
Interviewers also asked each parent for county of residence, from which geographic region
within North Carolina (Eastern, Piedmont [central], or Western) was determined. We also
classified households as “urban” (in a metropolitan statistical area) or “rural” (outside of an
metropolitan statistical area) based on residence location.18
For use in analyses, we separately gathered data on characteristics of counties where
respondents lived. Demographic variables based on Census 2000 data included percent of
population within each county aged 5 to 17 years, percent aged 25 years and older who were
high school graduates (or had higher education), percent minority female, and percent who
spoke a language other than English in the home.19 We obtained data from the SCHS on the
percent of population within each county living below the federal poverty level and the
number of persons per healthcare professional.20 The SCHS also provided data on age-
adjusted 10-year cervical cancer incidence and mortality rates (1997–2006), as well as teen
pregnancy rates (2005–2007). For 8 counties whose incidence rates were unavailable due to
a small number of cases, we used the lowest reported 10-year incidence rate among the
counties.
Data Analysis
We used logistic regression models to identify bivariate correlates of HPV vaccine initiation.
We then entered statistically significant bivariate predictors (P < 0.05) into a multivariate
logistic regression model. Among parents of unvaccinated females, we used linear
regression to determine if intent to vaccinate within the next year differed by demographic
factors thought to be important to HPV vaccine initiation (daughter’s age21) or cervical
cancer incidence (daughter’s race22 and urbanicity23). Analyses applied sampling weights to
account for the study design, though frequencies are not weighted. Statistical tests using
Intercooled Stata Version 10.1 (College Station, TX) were 2-tailed with a critical α of 0.05.
RESULTS
Participant Characteristics
The daughters’ mean age was 13.6 (standard deviation [SD] = 2.4) years old, with
comparable numbers across all 3 age groups (10–12, 13–15, and 16–17 years old) (Table 1).
Most parents reported their daughters attended a public school (87.9%), had some form of
healthcare coverage (95.0%), had a regular healthcare provider (85.8%), and had received a
preventive check-up within the last year (81.3%). A majority of parents indicated their
daughters were non-Hispanic white (67.6%) or non-Hispanic black (20.3%), with fewer
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indicating their daughters were another race or ethnicity (12.0%, including Hispanic [n = 35,
6.7%]).
A majority of parents were of age 40 or older (68.4%), female (83.2%), married or member
of an unmarried couple (76.5%), and employed (68.7%). Most households had an income of
$50,000 or more (56.7%), contained a person with at least some college education (81.5%),
and were located in an urban area (70.4%).
HPV Vaccine Initiation
Overall, 198 of 617 (31.3%, 95% confidence interval [CI]: 26.8%–36.1%) of parents
reported their daughters had received at least 1 dose of HPV vaccine. Among those who
reported vaccine initiation, most parents indicated that their daughters received HPV vaccine
from either their family doctors/general practitioners (58.1%) or pediatricians (33.6%). Few
parents reported obtaining vaccine from public or community clinics (3.9%), obstetrician-
gynecologists (1.6%), or elsewhere (2.9%).
HPV vaccination was far less common among daughters aged 10 to 12 years (18.8%)
compared with daughters aged 13 to 15 years (33.2%) or 16 to 17 years (45.2%) (both P <
0.05 in bivariate analyses). Vaccine initiation was also higher in bivariate analyses among
daughters who had a regular healthcare provider, had a preventive check-up in the last 12
months, had received meningococcal vaccine, lived in an urban area, or resided in counties
with higher percentages of the population who spoke a language other than English in their
home (all P < 0.05) (Tables 2 and 3). Parents who were currently employed or reported
receiving flu vaccine in the last year for themselves were more likely to report HPV vaccine
initiation (both P < 0.05).
In multivariate analyses (Table 4), vaccine initiation was higher among daughters who were
13 to 15 years old (odds ratio [OR] = 2.03, 95% CI, 1.12–3.67) or 16 to 17 years old (OR =
3.21, 95% CI, 1.76 –5.86), had a preventive check-up in the last 12 months (OR = 5.09, 95%
CI, 2.43–10.67), had received meningococcal vaccine (OR = 2.50, 95% CI, 1.55–4.01), or
were from an urban area (OR = 1.81, 95% CI, 1.02–3.21). Parents were also more likely to
report HPV vaccine initiation among their daughters if they had received flu vaccine in the
last year for themselves (OR = 2.03, 95% CI, 1.26 –3.26).
Reasons for Not Vaccinating and Intentions to Vaccinate
Among parents of unvaccinated daughters (n = 419), the most commonly reported reasons
for not vaccinating was not knowing enough or needing more information about the vaccine
(20.8%) and believing their child was too young for HPV vaccine (20.4%). Other frequently
indicated reasons included concerns about vaccine safety or side effects (13.4%), believing
the vaccine was too new (12.7%), not having a healthcare provider recommend the vaccine
(12.7%), and reporting their daughter was not sexually active yet (5.1%). All other reasons
were reported by less than 5% of parents. Interestingly, only 0.6% (n = 3) of parents
reported their daughters had not received HPV vaccine yet because the vaccine might
promote sexual activity.
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Parents of unvaccinated daughters expressed only moderate intent to get their daughters
HPV vaccine within the next year (mean = 2.39, SD = 1.01) (42.3%, 173/419 indicated
“probably will” or “definitely will”). Compared with parents of unvaccinated daughters aged
10 to 12 years, parents of unvaccinated daughters aged 13 to 15 years (2.52 vs. 2.20, t =
2.34, P = 0.019) or 16 to 17 years (2.54 vs. 2.20, t = 2.34, P = 0.019) reported higher levels
of intent to vaccinate in the next year. Intent did not differ between parents of unvaccinated
daughters in the 2 older age groups (P = 0.874). Parents of unvaccinated non-Hispanic white
daughters reported similar levels of intent compared with parents of unvaccinated non-
Hispanic black daughters (2.28 vs. 2.47, t = −1,31, P = 0.190), but lower levels of intent
compared with parents of unvaccinated daughters of other races (2.28 vs. 2.79, t = −2.98, P
= 0.003). Intent did not differ between parents of unvaccinated non-Hispanic black
daughters and parents of unvaccinated daughters in other racial groups (P = 0.099). Intent
levels among parents of unvaccinated daughters in urban areas did not differ from those in
rural areas (2.36 vs. 2.43, t = −0.55, P = 0.580).
DISCUSSION
If widespread HPV vaccination is achieved in the United States, cervical cancer incidence
may be greatly reduced.8 Among a statewide sample of North Carolina parents, we found
less than a third reported their adolescent daughters had received any doses of HPV vaccine.
While this estimate is much lower than that of nations with school-based HPV vaccine
programs,24,25 it is only slightly below the national average among adolescent females from
the United States in 2008.13 Our previous study involving 5 counties in North Carolina
reported only 10% of similarly aged adolescent females had initiated the HPV vaccine
regimen in 2007.21 Thus, HPV vaccine initiation among adolescent females appears to be
increasing as time since HPV vaccine licensure passes.
HPV vaccination likely offers the greatest benefit if administered before sexual debut.12,26
However, both HPV vaccine initiation and parents’ intent to vaccinate within the next year
were lower for younger daughters, including those in the recommended age range for
vaccination (11–12 years).12 Our results coincide with previous findings regarding vaccine
initiation21,27 and intentions.28,29 Although most older adolescent females (aged 14–19
years) are seronegative for all HPV types contained in the quadrivalent HPV vaccine30 and
may therefore still derive full benefit from the vaccine, future efforts should still consider
targeting younger females for HPV vaccination. Almost half of females in the United States
are sexually active during high school,31 and about 9% of females aged 14 to 19 years have
serologic evidence of infection with at least 1 HPV type contained in the quadrivalent
vaccine.30 Furthermore, analyses have shown that the cost-effectiveness of HPV vaccination
is optimized when there is high vaccination coverage among younger adolescent females.32
Vaccine initiation was higher among females from urban areas, which is concerning since
women in rural areas have higher cervical cancer incidence rates.23 Although we did not
find lower HPV vaccine coverage in rural areas previously,21 this study was conducted
among 5 counties clustered in the same geographic area. Residents of rural areas may face
additional barriers to receiving healthcare, including HPV vaccine, such as fewer healthcare
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providers and having to travel longer distances to healthcare.33,34 Rural residents represent
an important target population for future HPV vaccine research.
With cervical cancer incidence rates higher among blacks,22 it is encouraging that they had
similar levels of HPV vaccine initiation as non-Hispanic whites. Such findings are
promising in that HPV vaccine may help reduce the existing cervical cancer racial
disparities. We do wish to note that in exploratory analyses, daughters identified as Hispanic
had lower levels of vaccine initiation compared with all other racial groups (P < 0.05; data
not shown), though further analyses were not conducted due to the small number of
vaccinated Hispanic daughters (n = 5). While parents of unvaccinated Hispanic daughters
reported high intentions to vaccinate in the next year (data not shown), future research
addressing HPV vaccination among Hispanics is warranted.
The strongest correlate of HPV vaccine initiation was parents reporting their daughter had a
preventive check-up in the last year. One potential reason for this finding is that a healthcare
provider recommended HPV vaccination during the check-up, as provider’s
recommendation has been correlated with vaccine initiation previously.21,35 Only 36.3% of
parents who indicated their daughter had a preventive check-up in the last year, however,
also reported HPV vaccine initiation, suggesting there are still many missed opportunities by
healthcare providers to encourage and administer HPV vaccine to adolescent females during
these check-ups.
Parents were more likely to report their daughter had received HPV vaccine if they had also
received meningococcal vaccine. Although data were not available concerning the
temporality of receiving these vaccines, results underscore the potential to increase HPV
vaccine initiation by administering it concomitantly with other adolescent vaccines. Because
HPV vaccine has no components that might adversely affect safety or efficacy of other
vaccines, the Advisory Committee on Immunization Practices currently states that HPV
vaccine can be administered at the same visit as other adolescent vaccines, and that doing so
increases the likelihood that adolescents will receive each vaccine on schedule.12
The association observed between parental flu vaccination and HPV vaccination among
daughters may result from parents who receive flu vaccine utilizing health services for
themselves and their families more frequently. It is also possible that these parents have a
higher level of acceptance for vaccines in general.
Our study has several important strengths including a large, population-based sample of
parents and examining a wide range of potential correlates of HPV vaccine initiation. The
BRFSS and CHAMP surveys had good response rates and the capability to conduct
interviews in Spanish. In addition to being a cross-sectional study, there were other study
limitations. A different person, in some instances, was interviewed for the BRFSS and
CHAMP surveys. We relied solely upon parental reports of vaccination, though we found
the same level of HPV vaccine initiation as the state-specific estimate from the 2008
National Immunization Survey-Teen for North Carolina, which uses provider-verified
vaccination records.13 Some constructs that may be important to HPV vaccination, such as
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religious affiliation,36 were not measured in this research. Only parents who had a land line
telephone were interviewed, and the generalizability of the findings is not yet known.
In a statewide sample of North Carolina parents, just under one-third reported their
daughters had received one more doses of HPV vaccine. This level of vaccination coverage
is comparable with other recent estimates of HPV vaccination in the United States, yet
remains far lower than those observed in some other developed nations. Reducing missed
opportunities for vaccination at preventive check-ups and increasing concomitant
administration of adolescent vaccines may help increase HPV vaccination levels in the
United States.
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TABLE 1
Characteristics of Parents and Their Daughters (n = 617)
n Weighted % (95% CI)
Daughter characteristics
  Age (yr)
    10–12 198 36.9 (32.1–42.0)
    13–15 235 34.7 (30.2–39.5)
    16–17 184 28.4 (24.2–33.0)
  Race
    Non-Hispanic white 450 67.6 (62.7–72.3)
    Non-Hispanic black 89 20.3 (16.3–25.0)
    Other 78 12.0 (9.2–15.6)
  School type*
    Public 544 87.9 (84.2–90.8)
    Private/home schooled 69 12.1 (9.2–15.8)
  Healthcare coverage
    No 33 5.0 (3.2–7.6)
    Yes 584 95.0 (92.4–96.8)
  Regular healthcare provider
    No/don’t know 90 14.2 (11.2–18.0)
    Yes 527 85.8 (82.0–88.8)
  Preventive check-up in last 12 mo
    No/don’t know 120 18.7 (15.2–22.8)
    Yes 497 81.3 (77.2–84.8)
Parent characteristics
  Age (yr)†
    ≤39 164 31.6 (27.0–36.6)
    40–49 303 48.9 (43.9–53.8)
    ≥50 150 19.5 (16.1–23.5)
  Sex
    Female 513 83.2 (79.1–86.6)
    Male 104 16.8 (13.4–20.9)
  Marital status†
    Married/member of unmarried couple 474 76.5 (72.0–80.4)
    Other (divorced, widowed, separated, never married) 143 23.5 (19.6–28.0)
  Employment status†
    Employed for wages/self-employed 448 68.7 (63.7–73.2)
    Other (unemployed, homemaker, student, retired, unable to work) 169 31.3 (26.8–36.3)
Household characteristics
  Annual household income†
    <$50,000 231 35.5 (31.0–40.4)
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n Weighted % (95% CI)
    ≥$50,000 343 56.7 (51.7–61.5)
    Not reported 43 7.8 (5.4–11.1)
  Highest education level in household
    High school or less 115 18.5 (14.8–22.8)
    Some college or more 502 81.5 (77.2–85.2)
Characteristics of county of residence
  Geographic region†
    Western 107 14.3 (11.6–17.4)
    Piedmont 316 59.6 (55.1–63.9)
    Eastern 194 26.2 (22.6–30.1)
  Urbanicity†‡
    Urban 426 70.4 (65.9–74.5)
    Rural 191 29.6 (25.6–34.1)
Percents may not sum too 100% due to rounding.
*
Does not include parents who indicated they did not know their daughter’s school type (n = 2) or that their daughter was not in school (n = 2).
Private and home schooled were combined due to the small number of parents reporting their daughters were home schooled (n = 20).
†
Data collected during Behavioral Risk Factor Surveillance System (BRFSS) survey. All other data collected during Child Health Assessment and
Monitoring Program (CHAMP) survey.
‡
Urban defined as within a metropolitan statistical area (MSA) and rural defined as outside of an MSA.
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TABLE 2
Categorical Correlates of HPV Vaccine Initiation Among Daughters (n = 617)
No. Parents Reporting Their
Daughters Had Received
HPV Vaccine/Total No. Parents




  Age (yr)
    10–12 36/198 (18.8) Ref.
    13–15 85/235 (33.2) 2.14 (1.22–3.76)*
    16–17 77/184 (45.2) 3.56 (1.99–6.37)†
  Race
    Non-Hispanic white 150/450 (31.6) Ref.
    Non-Hispanic black 26/89 (32.3) 1.03 (0.57–1.88)
    Other 22/78 (27.6) 0.83 (0.42–1.64)
  School type‡
    Public 176/544 (32.4) 1.65 (0.87–3.16)
    Private/home schooled 20/69 (22.5) Ref.
  Healthcare coverage
    No 5/33 (16.3) Ref.
    Yes 193/584 (32.1) 2.43 (0.71–8.30)
  Regular healthcare provider
    No/don’t know 18/90 (16.8) Ref.
    Yes 180/527 (33.7) 2.52 (1.29–4.91)*
  Preventive check-up in last 12 mo
    No/don’t know 13/120 (9.4) Ref.
    Yes 185/497 (36.3) 5.53 (2.54–12.03)†
  Received meningococcal vaccine
    No/don’t know 52/231 (18.1) Ref.
    Yes 146/386 (39.3) 2.94 (1.84–4.68)†
Parent characteristics
  Age (yr)§
    ≤39 46/164 (26.4) Ref.
    40–49 98/303 (32.2) 1.32 (0.79–2.23)
    ≥50 54/150 (36.9) 1.63 (0.90–2.95)
  Sex
    Female 168/513 (31.0) Ref.
    Male 30/104 (32.7) 1.08 (0.61–1.93)
  Marital status§
    Married/member of unmarried couple 142/474 (29.9) 0.76 (0.47–1.25)
    Other (divorced, widowed, separated, never married) 56/143 (35.8) Ref.
  Employment status§
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No. Parents Reporting Their
Daughters Had Received
HPV Vaccine/Total No. Parents
in Category (Weighted %)
Bivariate OR
(95% CI)
    Employed for wages/self-employed 155/448 (34.8) 1.73 (1.04–2.85)*
    Other (unemployed, homemaker, student, retired, unable to work) 43/169 (23.6) Ref.
  Flu vaccine in the past year (shot or spray)§
    No/don’t know 110/400 (23.9) Ref.
    Yes 88/217 (45.0) 2.60 (1.67–4.05)†
  Pap smear within the last 3 yr§¶
    No 19/56 (28.1) Ref.
    Yes 128/353 (34.2) 1.33 (0.64–2.76)
  Any doses of HPV vaccine (mother)§¶
    No/don’t know 97/284 (32.5) Ref.
    Yes 13/36 (33.9) 1.07 (0.42–2.70)
Frequency children should be seen by healthcare provider for a check-up
  Less frequent than once a year/don’t know 11/50 (27.1) Ref.
  At least once a year 187/567 (31.6) 1.24 (0.56–2.76)
Household characteristics
  Annual household income§
    <$50,000 73/231 (31.8) Ref.
    ≥$50,000 108/343 (30.3) 0.93 (0.59–1.48)
    Not reported 17/43 (35.7) 1.19 (0.51–2.77)
  Highest education level in household
    High school or less 38/115 (36.7) Ref.
    Some college or more 160/502 (30.0) 0.74 (0.42–1.30)
  No. children under age 18 in household§
    1 103/292 (36.3) Ref.
    ≥2 95/325 (29.3) 0.72 (0.48–1.09)
Characteristics of county of residence
  Geographic region§
    Western 25/107 (22.9) Ref.
    Piedmont 118/316 (34.0) 1.74 (0.92–3.28)
    Eastern 55/194 (29.5) 1.41 (0.71–2.82)
  Urbanicity§‖
    Rural 45/191 (21.3) Ref.






Does not include parents who indicated they did not know their daughter’s school type (n = 2) or that their daughter was not in school (n = 2).
§
Data collected during Behavioral Risk Factor Surveillance System (BRFSS) survey. All other data collected during Child Health Assessment and
Monitoring Program (CHAMP) survey.
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¶
Not asked to all BRFSS respondents.
‖
Urban defined as within a metropolitan statistical area (MSA) and rural defined as outside of an MSA. HPV indicates human papillomavirus; OR,
odds ratio; CI, confidence interval; Ref., referent group.
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TABLE 3
Continuous Correlates of HPV Vaccine Initiation Among Daughters (n = 617)









Characteristics of county of residence
  Percent aged 5–17 yr 17.68 (1.67) 17.66 (1.35) 1.01 (0.86–1.20)
  Percent aged 25 and older who are high school graduate (or have higher education) 79.48 (7.77) 78.42 (7.31) 1.02 (0.99–1.06)
  Percent minority female 13.80 (8.34) 12.43 (7.64) 1.02 (1.00–1.05)
  Percent who speak a language other than English in the home 8.66 (3.44) 7.82 (3.40) 1.08 (1.01–1.16)*
  Percent living below federal poverty level 12.03 (4.15) 11.89 (3.73) 1.01 (0.95–1.07)
  Persons per healthcare professional 859.63 (564.36) 934.64 (522.18) 1.00 (1.00–1.00)
  10-yr cervical cancer incidence rate (per 100,000 women) 8.36 (2.13) 8.18 (1.80) 1.06 (0.94–1.19)
  10-yr cervical cancer mortality rate (per 100,000 women) 2.64 (1.09) 2.65 (0.93) 0.99 (0.78–1.25)




HPV indicates human papillomavirus; SD, standard deviation; OR, odds ratio; CI, confidence interval.
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TABLE 4




  Age (yr)
    10–12 Ref.
    13–15 2.03 (1.12–3.67)*
    16–17 3.21 (1.76–5.86)†
  Regular healthcare provider
    No/don’t know Ref.
    Yes 1.92 (0.86–4.26)
  Preventive check-up in last 12 mo
    No/don’t know Ref.
    Yes 5.09 (2.43–10.67)†
  Received meningococcal vaccine
    No/don’t know Ref.
    Yes 2.50 (1.55–4.01)†
Parent characteristics
  Employment status‡
    Employed for wages/self-employed 1.60 (0.95–2.69)
    Other (unemployed, homemaker, student, retired, unable to work) Ref.
  Received flu vaccine in the past year (shot or spray)‡
    No/don’t know Ref.
    Yes 2.03 (1.26–3.26)*
Characteristics of county of residence
  Urbanicity‡§
    Urban 1.81 (1.02–3.21)*
    Rural Ref.
  Percent of population who speak a language other than English in the home 1.02 (0.94–1.11)






Data collected during Behavioral Risk Factor Surveillance System (BRFSS) survey.
§
Urban defined as within a metropolitan statistical area (MSA) and rural defined as outside of an MSA.
HPV indicates human papillomavirus; OR, odds ratio; CI, confidence interval; Ref., referent group.
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